ArticleHuman vaccines & immunotherapeutics2021
Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Article
- Available evidence on the co-administration of the four-component meningococcal B vaccine (4CMenB) with three vaccines at the same visit among pediatric individuals.Human vaccines & immunotherapeutics · 2024Review
- Italian immunization calendar implementation: Time to optimize number of vaccination appointments?Human vaccines & immunotherapeutics · 2023Article
- Insights and expectations of healthcare professionals on the implementation of the updated pediatric regional immunization Calendar in Calabria, Italy.Human vaccines & immunotherapeutics · 2023Article
- Article
- The Value of Rotavirus Vaccination in Europe: A Call for Action.Infectious diseases and therapy · 2023Article
- Probiotics combined with zinc and selenium preparation in the treatment of child rotavirus enteritis.American journal of translational research · 2022Article
- Fourteen years' clinical experience and the first million babies protected with human live-attenuated vaccine against rotavirus disease in Italy.Human vaccines & immunotherapeutics · 2021Article
- Letter to the editor in response to: Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence.Human vaccines & immunotherapeutics · 2021Article
- Reply letter in response to "Letter to the editor in response to: Rotavirus vaccine administration patterns in Italy: potential impact on vaccine coverage, compliance and adherence, Martinelli D et al., Human Vaccines & Immunotherapeutics 2020" by Carias and colleagues.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acceptance of rotavirus (RV) vaccination may be impacted by several factors including the feasibility of the full schedule administration within the fixed immunization timelines. The human RV vaccine Rotarix (GSK) and the human bovine reassortant vaccine RotaTeq (Merck & Co.) were developed with different posologies (2 doses vs 3 doses respectively), which have both scientific and technical implications. A non-systematic literature review revealed that, in the Italian context, topics such as time to achieve RV protection in children, number of preventable cases and administration time window, compatibility/ease of inclusion in the national vaccination calendar, potential overlaps with the peak of natural history of intussusception and adherence to posology could be impacted by the RV vaccine posology. Results suggest that a shorter schedule would allow for greater flexibility of use as well as a greater documented ease of inclusion in the vaccination calendar, thereby reducing potential direct healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.